Nanocarrier therapy for treating invasive tumors
AssigneesEmory University, Georgia Tech Research Corporation, Children's Healthcare of Atlanta, Inc.
InventorsJennifer M. Munson, Ravi V. Bellamkonda, Jack L. Arbiser
Life of this patent
Estimating the term…
Abstract
Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis. The liposomes include cholesterol and chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms, such as distearoylphosphatidyl choline, and can also include one or more pegylated phospholipids, such as DSPE-PEG.
Claims8
A composition for treating tumors in a patient, comprising unilamellar liposomes containing a therapeutic amount of imipramine blue, or a pharmaceutically-acceptable salt thereof, in a pharmaceutically-acceptable carrier for intraveneous administration,
- wherein the liposomes comprise chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms.
Dependencies are inferred from the claim text.